Abstracts Archive - Page 1551 of 2425 - ACR Meeting Abstracts

Abstract Number: 2006 • 2016 ACR/ARHP Annual Meeting
Tuberculosis Incidence in Ankylosing Spondylitis, Psoriatic Arthritis, and Other Spondyloarthropathies in Sweden: A Population-Based Cohort Study
Mirjam K. de Vries¹, Elizabeth V. Arkema¹, Jerker Jonsson², Judith Bruchfeld³, Lennart TH Jacobsson⁴ and Johan Askling^1,5, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Infectious Diseases Unit, Karolinska University Hospital, The Public Health Agency of Sweden, Stockholm, Sweden, ³Department of Medicine, Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁵Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are at a well-documented increased risk of tuberculosis (TB) compared to the general population, both with and without treatment…
Abstract Number: 2007 • 2016 ACR/ARHP Annual Meeting
Sensitivity and Specificity of Autoantibodies Against CD74 in Early Axial Spondyloarthritis
Torsten Witte¹, Elke Riechers², Niklas Thomas Baerlecken³, Xenofon Baraliakos⁴, Katrin Achilles-Mehr Bakhsh⁵, Peer Aries⁶, Bettina Bannert⁷, Klaus Becker⁸, Jan Brandt-Juergens⁹, Juergen Braun¹⁰, Boris P. Ehrenstein¹¹, Hartwig Euler¹², Martin Fleck¹³, Reinhard Hein¹⁴, Kirsten Karberg¹⁵, Lars Koehler¹⁶, Torsten Matthias¹⁷, Regina Max¹⁸, Adelheid Melzer¹⁹, Dirk Meyer-Olson²⁰, Juergen Rech²¹, Karin Rockwitz²², Martin Rudwaleit²³, Eva Schweikhard¹⁷, Joachim Sieper²⁴, Carsten Stille¹⁶, Ulrich von Hinüber²⁵, Peter Wagener²⁶, Heike Weidemann²⁷ and Silke Zinke¹⁵, ¹Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ²Medical University Hannover, Hannover, Germany, ³Clinical Immunology and Rheumatology, MD, Hannover, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumatology, Hannover, Hannover, Germany, ⁶Rheumatologie im Struenseehaus, Hamburg, Germany, ⁷Department of Internal Medicine, Clinic for Rheumatology and Clinical Immunology, Freiburg, Germany, ⁸Rheumapraxis Blaubeuren, Blaubeuren, Germany, ⁹Praxis Brandt-Juergens/Karberg, Berlin, Germany, ¹⁰Rheumazentrum Ruhrgebiet, Herne, Germany, ¹¹Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany, ¹²Rheumapraxis Hamburg, Hamburg, Germany, ¹³Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁴Rheumapraxis Nienburg, Nienburg, Germany, ¹⁵Rheumapraxis, Berlin, Germany, ¹⁶Rheumapraxis, Hannover, Germany, ¹⁷Aesku.Diagnostics, Wendelsheim, Germany, ¹⁸Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ¹⁹Rheumapraxis, Seesen, Germany, ²⁰m&i Fachklinik Bad Pyrmont, Bad Pyrmont, Germany, ²¹Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ²²Rheumatologic Practice, Goslar, Germany, ²³Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany, ²⁴Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ²⁵Rheumapraxis Hildesheim, Hildesheim, Germany, ²⁶Rheumapraxis, Nienburg, Germany, ²⁷Rheumapraxis Hannover, Hannover, Germany
Background/Purpose: Making the diagnosis of axial spondyloarthritis (axSpA) may be difficult. Antibodies against CD74 have been shown to be present in 2/3 of patients…
Abstract Number: 2008 • 2016 ACR/ARHP Annual Meeting
Rapamycin Elicits Rapid and Lasting Improvement of Disease Activity through Blocking Pro-Inflammatory T Cell Lineage Specification in Patients with Active SLE
Zhi-Wei Lai¹, Ivan Marchena², Hajra Tily², Ricardo Garcia¹, Julie Yu², Lisa Francis², Maha Dawood², Ryan Kelly², Stephen Faraone², Paul E. Phillips³ and Andras Perl⁴, ¹Medicine, SUNY, Syracuse, NY, ²SUNY, Syracuse, NY, ³Dept of Medicine/Div of Rheum, SUNY-Upstate Medical Univ, Syracuse, NY, ⁴Department of Medicine, Upstate Medical University, Syracuse, NY
Background/Purpose: The rationale for this prospective, biomarker-driven, open-label clinical trial of rapamycin (ClinicalTrials.gov Identifier: NCT00779194) has been based on growing evidence for involvement of the…
Abstract Number: 2009 • 2016 ACR/ARHP Annual Meeting
The Effect of Anifrolumab on Cutaneous Manifestations and Arthritis in Moderate to Severe Systemic Lupus Erythematosus (SLE) Using Categorical SLEDAI–2K Responses and Continuous Measures of Activity As Outcome Measures
JT Merrill¹, R Furie², Victoria P. Werth^3,4, M Khamashta⁵, J Drappa⁶, L Wang⁶ and G Illei⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Northwell Health, Great Neck, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Philadelphia V.A. Medical Center, Philidelphia, PA, ⁵Graham Hughes Lupus Research Laboratory, London, United Kingdom, ⁶MedImmune, Gaithersburg, MD
Background/Purpose: The Phase IIb MUSE study (NCT01438489) of intravenous anifrolumab in 305 patients with moderate to severely active SLE (300 or 1,000 mg vs. placebo,…
Abstract Number: 2010 • 2016 ACR/ARHP Annual Meeting
Predictive Factors of Adherence to Treatment in an International Prospective Study of Blood Hydroxychloroquine Levels in SLE Patients with Flares
Nathalie Costedoat-Chalumeau¹, Frédéric A. Houssiau², Peter M. Izmirly³, Véronique Le Guern⁴, Sandra V. Navarra⁵, Meenakshi Jolly⁶, Guillermo RUIZ-IRASTORZA⁷, Eric Hachulla⁸, Nancy Agmon-Levin⁹, Yehuda Shoenfeld¹⁰, Francesca Dall'Ara¹¹, Jill P. Buyon¹², Christophe Deligny¹³, Ricard Cervera¹⁴, Estibaliz Lazaro¹⁵, Holy Bezanahary¹⁶, Gabriel Baron¹⁷, Gaëlle Leroux¹⁸, Nathalie Morel⁴, Jean-Francois Viallard¹⁹, Christian Pineau²⁰, Lionel Galicier²¹, Ronald van Vollenhoven²², Angela Tincani²³, Hanh Nguyen²⁴, Guillaume Gondran²⁵, Noel Zahr²⁶, Jacques Pouchot²⁷, Jean Charles Piette²⁸, Michelle Petri²⁹ and David A. Isenberg³⁰, ¹Internal Medicine, Cochin University Hospital, Paris, France, ²Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ³New York University School of Medicine, New York, NY, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁶Rush, Chicago, IL, ⁷Cruces University Hospital, Barakaldo, Spain, ⁸Internal Medicine, Lille University Hospital, Lille, France, ⁹Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv, Israel, ¹⁰Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ¹¹University of Pavia, Pavia, Italy, ¹²Medicine, New York University School of Medicine, New York, NY, ¹³Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁴Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ¹⁵Centre François Magendie, CHU de Bordeaux, Pessac, France, ¹⁶Internal Medicine, University Hospital of Limoges, Limoges, France, ¹⁷Hôpital Hôtel Dieu, Paris, France, ¹⁸Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ¹⁹Internal Medecine, Haut Lévèque Hospital, Bordeaux, France, ²⁰Rheumatology, MUHC, Montreal, QC, Canada, ²¹Clinical Immunology, St Louis Hospital, Paris, France, ²²Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²⁴Centre of Rheumatology. Medicine., University College of London Hospital, london, United Kingdom, ²⁵Internal Medicine Department, Limoges, France, ²⁶Pitié Salpêtrière, Pharmacological, Pitié Salpêtrière, Paris, France, ²⁷Internal Medicine Department, European Hospital Georges Pompidou, Paris, France, ²⁸Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ²⁹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ³⁰Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Non-adherence to treatment, a major cause of continued lupus activity and flares, may be difficult to recognize. In this international prospective study, we evaluated…
Abstract Number: 2011 • 2016 ACR/ARHP Annual Meeting
Enteric-Coated Mycophenolate Sodium Versus Azathioprine for Patients with Moderate/Severe Active Systemic Lupus Erythematosus: Results from a Phase 3, Randomized, Parallel, Multicentre Study
Josefina Cortés-Hernández¹, luis Sáez-Comet², Mercedes Pérez-Conesa², M Rubio Rivas³, Francesca Mitjavila⁴, A. Castro Salomó⁵, Sandra Parra⁶, J. Cuquet Pedragosa⁷, Vera Ortiz-Santamaría⁸, M. Mauri Plana⁹, Segundo Bujan-Rivas¹⁰, P Suñé Martin¹¹, Xavier Vidal¹² and Josep Ordi-Ros¹³, ¹Internal Medicine Department, Vall d´Hebron Hospital, Barcelona, Spain, ²Internal Medicine, Miguel Servet University Hospital, Zaragoza, Spain, ³Internal Medicine, hopital Universitario Bellvitge, Barcelona, Spain, ⁴Internal Medicine, Bellvitge University Hospital, Barcelona, Spain, ⁵Hospital Universitari de Reus, Spain, Reus, Spain, ⁶Internal Medicine, Sant Joan de Reus University Hospital, Reus, Spain, ⁷Internal Medicine, Granollers University Hospital, Granollers, Spain, ⁸Rheumatology, Hospital General. Granollers., Granollers, Spain, ⁹Internal Medicine, Mataró Hospital, Mataró, Spain, ¹⁰Vall d'Hebron Hospital, Barcelona, Barcelona, Spain, ¹¹Pharmacy Department, Vall d'Hebron Hospital, Barcelona, Spain, ¹²Statistical Department, Vall d'Hebron Hospital, Barcelona, Spain, ¹³Internal Medicine, Systemic Autoimmune disease Research Unit. Hospital Vall d'Hebron., Barcelona, Spain
Background/Purpose: Treatment of non-renal manifestations in systemic lupus erythematosus (SLE) remains challenging. To date, available data on the efficacy, safety and steroid-sparing effects of non-biological…
Abstract Number: 2012 • 2016 ACR/ARHP Annual Meeting
Utility of the Lupus Low Disease Activity State Definition in Discriminating Responders in the Phase IIb Muse Trial of Anifrolumab in Systemic Lupus Erythematosus
E. Morand¹, A. Berglind², T. Sheytanova², R. Tummala³ and G. Illei³, ¹Monash University, Melbourne, Australia, ²AstraZeneca, Mölndal, Sweden, ³MedImmune, Gaithersburg, MD
Background/Purpose: Preliminary validation of a Lupus Low Disease Activity State (LLDAS) definition has demonstrated that LLDAS attainment is associated with reduced damage accrual in patients…
Abstract Number: 2013 • 2016 ACR/ARHP Annual Meeting
BIIB059, a Monoclonal Antibody Targeting BDCA2, Shows Evidence of Biological Activity and Early Clinical Proof of Concept in Subjects with Active Cutaneous SLE
Richard Furie¹, Victoria P. Werth², Joseph Merola³, Wenting Wang⁴, Dania Rabah⁴, Catherine Barbey⁴, Cynthia Carrillo-Infante⁴, Taylor Reynolds⁴, Lauren Stevenson⁴, David Martin⁴ and Nathalie Franchimont⁴, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA, ³Harvard Medical School, Boston, MA, ⁴Biogen, Cambridge, MA
Background/Purpose: Type I interferons (IFN-I) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). BDCA2 is a plasmacytoid dendritic cell (pDC)-specific receptor that, upon…
Abstract Number: 2014 • 2016 ACR/ARHP Annual Meeting
A Deep Insight into Causes and Predictors of Death in Systemic Sclerosis
Muriel Elhai¹, Christophe Meune², Jerome Avouac¹, Fazia Amrouche³, Eric Hachulla⁴, Alexandra Balbir-Gurman⁵, Gabriela Riemekasten⁶, Paolo Airò⁷, Patricia E. Carreira⁸, Yannick Allanore⁹ and on behalf of EUSTAR co-authors, ¹Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Paris XIII University, Bobigny, France, ³Paris Descartes University, Cochin Hospital, Paris, France, ⁴CHU Lille, Lille, France, ⁵B Shine Department of Rheumatology, Rambam Health Care Campus,. Rappaport Faculty of Medicine, Technion, Haifa, Israel, ⁶Department of Rheumatology, University of Luebeck, Lübeck, Germany, ⁷Rheumatology and Clinical immunology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁸Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁹Immunogenetics, Cochin Institute, Paris, France
Background/Purpose : Systemic sclerosis (SSc), a connective tissue disease, is associated with high mortality rates. The main causes and risk factors for death are…
Abstract Number: 2015 • 2016 ACR/ARHP Annual Meeting
The Systemic Sclerosis Disease State Is Associated with Specific Alterations in Gastrointestinal Microbiota in Two Independent Cohorts
Elizabeth R. Volkmann¹, Anna-Maria Hoffmann-Vold², Yu-Ling Chang³, Jonathan Jacobs⁴, Philip J. Clements⁴, Martin Kummen², Johannes R. Hov², Kirsten Tillisch¹, Venu Lagishetty¹, Oyvind Midtvedt⁵, Øyvind Molberg⁵ and Jonathan Braun³, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Oslo University Hospital, Oslo, Norway, ³Pathology and Laboratory Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Rheumatology, Oslo University Hospital, Oslo, Norway
Background/Purpose: A single center study demonstrated that systemic sclerosis (SSc) patients have a distinct colonic microbial consortium (based on lavage specimens) compared with healthy controls…
Abstract Number: 2016 • 2016 ACR/ARHP Annual Meeting
Esophageal Disease in Systemic Sclerosis: Does Heritability Play a Role?
Latifa Fakoya¹, Kathryn Peterson², Andrew Gawron², Jathine Wong³, Mary Beth Scholand⁴, Allen D. Sawitzke⁵ and Tracy M. Frech^6,7, ¹Internal Medicine/Rheumatology, University of Utah, Salt Lake City, UT, ²Internal Medicine/Gastroenterology, University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake, UT, ⁴University of Utah, Salt Lake City, UT, ⁵Rheumatology, Univ of Utah, Salt Lake City, UT, ⁶Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ⁷Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT
Background/Purpose: Systemic sclerosis (SSc) associated gastroesophageal reflux disease (GERD) can cause symptoms of dysphagia and heartburn, and is associated with esophagitis, stricture, Barrett’s esophagus, and…
Abstract Number: 2017 • 2016 ACR/ARHP Annual Meeting
Performance of Modified Rodnan Skin Score in Early Diffuse Cutaneous Scleroderma-Analysis from 4 International Cohorts
Dinesh Khanna¹, Susanna Proudman^2,3, Tracy M. Frech⁴, Svetlana Nihtyanova⁵, Robyn T. Domsic⁶, Veronica J. Berrocal⁷, Wendy Stevens⁸, Mandana Nikpour⁹ and Christopher P.Denton¹⁰, ¹University of Michigan, Ann Arbor, MI, ²Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ³Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁴Div of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT, ⁵Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, Royal Free Hospital, London, United Kingdom, ⁶Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁸Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁹Melbourne University, Melbourne, Australia, ¹⁰Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: The modified Rodnan skin score (mRSS) is used as a primary outcome measure in clinical trials of dcSSc. EUSTAR analysis has proposed that a…
Abstract Number: 2018 • 2016 ACR/ARHP Annual Meeting
A Clinical Risk Prediction Model for Skin Thickness Progression in Early Diffuse Scleroderma
Robyn T. Domsic¹, Mary Lucas², Virginia D. Steen³ and Thomas A. Medsger Jr.⁴, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh Scleroderma Center, Pittsburgh, PA, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) is a rapidly evolving field with multiple potential therapeutic agents under development and several active clinical trials focused on treating…
Abstract Number: 2019 • 2016 ACR/ARHP Annual Meeting
Faces in Motion: Clinical Subtyping in Scleroderma Using Changes in Forced Vital Capacity
Colin Ligon¹, Peter Schulam², Suchi Saria³, Fredrick M. Wigley⁴, Robert Wise⁵ and Laura K. Hummers⁶, ¹Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, PA, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Prognostication in scleroderma has historically depended on using static measures such as antibody status and extent of skin involvement to stratify risk of mortality…
Abstract Number: 2020 • 2016 ACR/ARHP Annual Meeting
Making the Case for Self-Management Education: Marketing Lessons Learned from Qualitative Research
Teresa J. Brady¹, Bithiah Lafontant², Tai Baker³ and Rebecca Ledsky⁴, ¹Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ²FHI 360, Washington, DC, ³Centers for Disease Control and Prevention, Atlanta, GA, ⁴Social Marketing and Communication, FHI 360, Washington, DC
Background/Purpose: Self-management education (SME) uses educational and behavioral strategies to help people with arthritis (PWA) and other chronic conditions (CC) develop healthy behaviors and gain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].